Johnson & Johnson announced that it has struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

The US healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental COVID-19 vaccine candidate, even before it has a signal that it works.

J&J plans to start human testing by September, with an eye on having it ready under an emergency use authorization in early 2021, far quicker than the typical 18-month period that it takes for vaccines to be tested, approved and then manufactured.

Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.

J&J and the U.S. government are investing $1 billion to create enough manufacturing capacity for the experimental vaccine candidate to stop the virus that has killed nearly 185,000 people around the globe.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.